LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Acute Sleep Loss Triggers Increase in Plasma Levels of Tau Protein in Young Adults

By LabMedica International staff writers
Posted on 20 Jan 2020
Print article
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
A team of Swedish researchers has found that acute sleep loss results in increased blood levels of t-tau protein, a key biomarker for nervous system disorders such as Alzheimer’s disease.

Previous studies had shown that disrupted sleep increased CSF (cerebrospinal fluid) levels of tau and beta-amyloid (ABeta) and was associated with an increased risk of Alzheimer’s disease (AD). The aim of the current study, conducted by investigators at Uppsala University (Sweden), was to determine whether acute sleep loss altered diurnal profiles of plasma-based AD-associated biomarkers.

The current study involved 15 healthy, normal-weight men with an average age of 22 years. The design of the experiment comprised two phases. For each phase, the subjects were housed in a sleep clinic for two days and nights under a strict meal and activity schedule. Blood samples were collected in the evening and again in the morning. For one phase, participants were allowed an uninterrupted night of sleep both nights. For the other phase, participants were allowed uninterrupted sleep the first night followed by a second night of sleep deprivation.

Plasma levels of total tau (t-tau), ABeta40, ABeta42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in the blood samples were assessed using ultrasensitive single molecule array assays or ELISAs,

Results revealed the after sleep deprivation, the subjects had an average 17% increase in tau levels in their blood. In contrast, following a night of interrupted sleep, the subjects had an average increase in tau levels of only 2%. No changes between the sleep conditions were seen for levels of ABeta40, ABeta42, NfL, or GFAP.

"Many of us experience sleep deprivation at some point in our lives due to jet lag, pulling an all-nighter to complete a project, or because of shift work, working overnights. or inconsistent hours," said senior author Dr. Jonathan Cedernaes, a senior researcher at Uppsala University. "Our exploratory study shows that even in young, healthy individuals, missing one night of sleep results in a slight increase in the level of tau in blood. This suggests that over time, similar types of sleep disruption could potentially have detrimental effects."

"It is important to note that while accumulation of tau in the brain is not good, in the context of sleep loss, we do not know what higher levels of tau in blood represent" said Dr. Cedernaes. "When neurons are active, release of tau in the brain is increased. Higher levels in the blood may reflect that these tau proteins are being cleared from the brain or they may reflect an overall elevation of the concentration of tau levels in the brain. Future studies are needed to investigate this further, as well as to determine how long these changes in tau last, and to determine whether changes in tau in blood reflects a mechanism by which recurrent exposure to restricted, disrupted or irregular sleep may increase the risk of dementia. Such studies could provide key insight into whether interventions targeting sleep should begin at an early age to reduce a person's risk of developing dementia or Alzheimer's disease."

The study was published in the January 8, 2020, online edition of the journal Neurology.

Related Links:
Uppsala University

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.